《American Journal Of Cardiovascular Drugs》雜志的最新年發(fā)文量為56篇。
這表明該刊在每年都會(huì)精選并發(fā)表一定數(shù)量的高質(zhì)量文章，以保持其在心臟和心血管系統(tǒng)領(lǐng)域的學(xué)術(shù)影響力。
該刊聚焦于醫(yī)學(xué)-心臟和心血管系統(tǒng)領(lǐng)域的前沿研究，致力于推動(dòng)該領(lǐng)域新技術(shù)和新知識(shí)的傳播與應(yīng)用。同時(shí)它積極鼓勵(lì)研究人員詳細(xì)發(fā)表其高質(zhì)量的實(shí)驗(yàn)研究和理論成果。
該刊的平均審稿周期約為 12周，或約稿 。
American Journal Of Cardiovascular Drugs 雜志發(fā)文統(tǒng)計(jì)
文章名稱引用次數(shù)
- Selective BET Protein Inhibition with Apabetalone and Cardiovascular Events: A Pooled Analysis of Trials in Patients with Coronary Artery Disease24
- Management of Statin Intolerance in 2018: Still More Questions Than Answers23
- Clinical Pharmacokinetics, Safety, and Tolerability of a Novel, First-in-Class TRPV4 Ion Channel Inhibitor, GSK279 in Healthy and Heart Failure Subjects23
- A Meta-Analysis of the Effect of PCSK9-Monoclonal Antibodies on Circulating Lipoprotein (a) Levels14
- Cardioprotection by Metformin: Beneficial Effects Beyond Glucose Reduction13
- The Effect of Bromodomain and Extra-Terminal Inhibitor Apabetalone on Attenuated Coronary Atherosclerotic Plaque: Insights from the ASSURE Trial11
- Clinical Use of Digitalis: A State of the Art Review10
- Pulmonary Arterial Hypertension: Combination Therapy in Practice9
- A Systematic Review on the Protective Effect of N-Acetyl Cysteine Against Diabetes-Associated Cardiovascular Complications9
- Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study9
國(guó)家/地區(qū)發(fā)文量
- USA89
- CHINA MAINLAND40
- Italy21
- England18
- France13
- Spain12
- Japan11
- Greece10
- Australia9
- Switzerland9
